Telitacicept, CAS 2136630-26-5

Product Description: Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Yao X, et, al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021 Apr 1;159:105704. /[2]Yuxi Yan, et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. Journal of Immunological Sciences. March 31, 2022.

CAS Number: 2136630-26-5

Molecular Weight: N/A

Compound Purity: 99.30

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Others

• Artikelnummer: MEXHY-P99568-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99568-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated